Rapid Medical™, a leading developer of advanced neurovascular devices, announced Chinese approval of its TIGERTRIEVER revascularization device. With this milestone approval from the National Medical Products Administration (NMPA), TIGERTRIEVER becomes the first device to offer patient-specific solutions to remove blood clots from the brain…
Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets. Longaevus Technologies is a company builder with dedicated to longevity, with an all-round approach to reversing aging based on its multiple hallmarks. Longaevus…
Novartis today announced new long-term data from ORION-8, a Phase III open-label extension of ORION-9, ORION-10, ORION-11 and ORION-3 trials. The data demonstrated that with twice-yearly* dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction…
Sandoz, a global leader in generic and biosimilar medicines, has successfully completed the acquisition of worldwide brand rights for leading systemic antifungal agent Mycamine ® (micafungin sodium, Funguard® in Japan) from Astellas. Through this acquisition of the leading global echinocandin, one of three…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, being evaluated for…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor…
Serengen and Deargen are excited to announce their collaboration to accelerate the drug discovery process. This strategic partnership brings together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s leading AI-driven drug discovery platform, known as DearDTI. The world of drug discovery is…
The “Esophagoscopes Market Size by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures and Forecast to 2033” database has been added to ResearchAndMarkets.com’s offering. This report was built to visualize quantitative market trends within Endoscopy Devices therapeutic area. The model discusses…
RQM+, the global leader in medtech services, announces the acquisition of CRO Kottmann, a leading contract research organization (CRO) renowned for its unparalleled customer service, clinical research and its commitment to quality in the key German market. This major transaction confirms…
Anthem Blue Cross and Blue Shield in Connecticut today announced its Anthem Link Virtual First health plans to eligible members in select commercial health plans. Anthem Link Virtual First plans give individuals affordable access to virtual care options, including access…
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Reblozyl® (luspatercept-aamt) for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who…
LIB Therapeutics Inc., a clinical-stage biopharmaceutical company developing subcutaneous and oral PCSK9 inhibitor medicines for patients at very high and high risk of cardiovascular disease (“CVD”) requiring additional reductions in LDL- cholesterol (“LDL-C” or “LDL”), in patients on maximally tolerated…